Gene of the month:PIK3CA

Sequencing the head and neck cancer genome: implications for therapy

(2014) Wenyue Sun et al.   Annals of the New York Academy of Sciences

The significance of autophagy in colorectal cancer pathogenesis and implications for therapy

(2014) K Lai et al.   JOURNAL OF CLINICAL PATHOLOGY

Characterization of the Novel and Specific PI3K  Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

(2014) C. Fritsch et al.   MOLECULAR CANCER THERAPEUTICS

Combined mutational analysis of RAS, BRAF, PIK3CA, and TP53 genes in Taiwanese patients with oral squamous cell carcinoma

(2014) Ya-Sian Chang et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Biological Basis for Increased Sensitivity to Radiation Therapy in HPV-Positive Head and Neck Cancers

(2014) V. Bol et al.   Biomed Research International

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

(2013) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Genetic deregulation of the PIK3CA oncogene in oral cancer

(2013) Avaniyapuram Kannan Murugan et al.   CANCER LETTERS

Phosphoinositide 3-kinases as accelerators and brakes of autophagy

(2013) Fergal O′Farrell et al.   FEBS Journal

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer

(2013) Sherene Loi et al.   JNCI-Journal of the National Cancer Institute

Regulation and cellular functions of class II phosphoinositide 3-kinases

(2012) Marco Falasca et al.   BIOCHEMICAL JOURNAL

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

(2012) X. Liao et al.   CLINICAL CANCER RESEARCH

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

(2012) S. Chandarlapaty et al.   CLINICAL CANCER RESEARCH

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition

(2012) Natalie R. Young et al.   Molecular Oncology

Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer Survival

(2012) Xiaoyun Liao et al.   NEW ENGLAND JOURNAL OF MEDICINE

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

(2011) C. Mao et al.   ANNALS OF ONCOLOGY

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

(2011) Leiping Wang et al.   BMC CANCER

Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes

(2011) Sandrine Boyault et al.   BREAST CANCER RESEARCH AND TREATMENT

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

(2011) E. Razis et al.   BREAST CANCER RESEARCH AND TREATMENT

Oncogenic PIK3CA mutations in colorectal cancers and polyps

(2011) Vicki L.J. Whitehall et al.   INTERNATIONAL JOURNAL OF CANCER

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

(2010) Francisco J. Esteva et al.   AMERICAN JOURNAL OF PATHOLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Oncogenic mutations as predictive factors in colorectal cancer

(2010) A Lièvre et al.   ONCOGENE

Absence of hotspot mutations in exons 9 and 20 of the PIK3CA gene in human oral squamous cell carcinoma in the Greek population

(2010) George C. Kostakis et al.   ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS

Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma

(2010) Q.-W. Fan et al.   Science Signaling

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

(2009) Y. He et al.   CLINICAL CANCER RESEARCH

PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

(2009) K. Kalinsky et al.   CLINICAL CANCER RESEARCH

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers

(2008) Ludovic Barault et al.   INTERNATIONAL JOURNAL OF CANCER

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE